Can deep sleep or nerve stimulation protect the brain? new trial aims to find out
NCT ID NCT06421532
First seen Nov 01, 2025 · Last updated Jun 23, 2026 · Updated 39 times
Summary
This phase 2 trial tests whether a sleep-deepening drug (lower-sodium oxybate) and/or a nerve-stimulating device (non-invasive vagus nerve stimulation) can help the brain clear harmful amyloid proteins in people with cerebral amyloid angiopathy (CAA). Sixty participants will receive one or both treatments for three months. The study measures changes in spinal fluid amyloid levels and brain imaging markers to see if these approaches can slow disease progression.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CEREBRAL AMYLOID ANGIOPATHY are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Leiden University Medical Center (LUMC)
Leiden, 2333ZA, Netherlands
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
lower-sodium oxybate (XYWAV) and non-invasive vagus nerve stimulation (gammaCore Sapphire)
What this could lead to
If successful, this could point toward a new way to slow or prevent brain bleeding and cognitive decline in people with cerebral amyloid angiopathy.
What could go wrong
This is a small, early-phase trial (60 participants) testing biological markers, not clinical outcomes. The treatments may not improve symptoms or disease progression, and side effects like dizziness or nausea are possible.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.